> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Ovrette Not Withdrawn Due to Safety/Effectiveness: FDA
- URL: https://www.fdaweb.com/ovrette-not-withdrawn-due-to-safety-effectiveness-fda/
- Published: 2017-10-25T12:00:00.000Z
- Updated: 2026-09-14T22:58:02.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139966

*Federal Register* notice: FDA has determined that HRA Pharma’s Ovrette (norgestrel) tablets, 0.075 mg, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve ANDAs referencing the product if all other legal and regulatory requirements are met. The FDA action as requested by The Weinberg Group in a February citizen petition. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-10-25/pdf/2017-23125.pdf?ref=fdaweb.com).